The stock of Coeptis Therapeutics Holdings Inc (COEP) has gone up by 18.74% for the week, with a 6.03% rise in the past month and a 20.23% rise in the past quarter. The volatility ratio for the week is 13.08%, and the volatility levels for the past 30 days are 10.19% for COEP. The simple moving average for the past 20 days is 8.43% for COEP’s stock, with a -19.52% simple moving average for the past 200 days.
Is It Worth Investing in Coeptis Therapeutics Holdings Inc (NASDAQ: COEP) Right Now?
Company’s 36-month beta value is -0.90.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for COEP is 29.57M, and currently, short sellers hold a 0.92% ratio of that floaft. The average trading volume of COEP on December 18, 2024 was 412.90K shares.
COEP) stock’s latest price update
The stock price of Coeptis Therapeutics Holdings Inc (NASDAQ: COEP) has jumped by 10.47 compared to previous close of 0.19. Despite this, the company has seen a gain of 18.74% in its stock price over the last five trading days. prnewswire.com reported 2024-12-12 that Coeptis Technologies Signs Binding Letter of Intent to Acquire Key Assets from a Risk Mitigation Software Company with 10,000 customers in over 100 countries, Expanding into the Booming Data Security Sector following the upcoming acquisition of NexGenAI Affiliates Network WEXFORD, Pa., Dec. 12, 2024 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the official launch of Coeptis Technologies, a new division aimed at diversifying and enhancing the company’s growth potential.
COEP Trading at 6.17% from the 50-Day Moving Average
After a stumble in the market that brought COEP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.25% of loss for the given period.
Volatility was left at 10.19%, however, over the last 30 days, the volatility rate increased by 13.08%, as shares surge +7.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.48% upper at present.
During the last 5 trading sessions, COEP rose by +18.74%, which changed the moving average for the period of 200-days by -60.85% in comparison to the 20-day moving average, which settled at $0.1946. In addition, Coeptis Therapeutics Holdings Inc saw -73.08% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at COEP starting from Cogley Brian, who purchase 5,000 shares at the price of $0.67 back on Jan 10 ’24. After this action, Cogley Brian now owns 30,000 shares of Coeptis Therapeutics Holdings Inc, valued at $3,350 using the latest closing price.
DeSilva Tara, the Director of Coeptis Therapeutics Holdings Inc, purchase 2,266 shares at $0.58 during a trade that took place back on Jan 12 ’24, which means that DeSilva Tara is holding 32,266 shares at $1,305 based on the most recent closing price.
Stock Fundamentals for COEP
Current profitability levels for the company are sitting at:
- -7.5 for the present operating margin
- 0.21 for the gross margin
The net margin for Coeptis Therapeutics Holdings Inc stands at -7.74. The total capital return value is set at -2.04. Equity return is now at value -205.37, with -127.52 for asset returns.
Based on Coeptis Therapeutics Holdings Inc (COEP), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -4.05. The debt to equity ratio resting at 0.35. The interest coverage ratio of the stock is -33.98.
Currently, EBITDA for the company is -20.16 million with net debt to EBITDA at -0.06. When we switch over and look at the enterprise to sales, we see a ratio of 6.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.40.
Conclusion
In a nutshell, Coeptis Therapeutics Holdings Inc (COEP) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
